Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)

Paolo A. Ascierto; Lisa H. Butterfield; Katie Campbell; Bruno Daniele; Michael Dougan; Leisha A. Emens; Silvia Formenti; Filip Janku; Samir N. Khleif; Tomas Kirchhoff; Alessandro Morabito; Yana Najjar; Paul Nathan; Kunle Odunsi; Akash Patnaik; Chrystal M. Paulos; Bradley I. Reinfeld; Heath D. Skinner; John Timmerman; Igor Puzanov

doi:10.1186/s12967-020-02627-y

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)

Paolo A. Ascierto, Lisa H. Butterfield, Katie Campbell, Bruno Daniele, Michael Dougan, Leisha A. Emens, Silvia Formenti, Filip Janku, Samir N. Khleif, Tomas Kirchhoff, Alessandro Morabito, Yana Najjar, Paul Nathan, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Bradley I. Reinfeld, Heath D. Skinner, John Timmerman, Igor Puzanov

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4–5 December, 2019, Naples, Italy), and are summarised in this report.

Original language	English (US)
Article number	13
Journal	Journal of translational medicine
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s12967-020-02627-y
State	Published - Dec 2021

Keywords

Biomarkers
Checkpoint inhibitors
Combination therapy
Immunotherapy
Tumor microenvironment
Vaccine

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

MD Anderson CCSG core facilities

Clinical and Translational Research Center

Access to Document

10.1186/s12967-020-02627-y

Cite this

Ascierto, P. A., Butterfield, L. H., Campbell, K., Daniele, B., Dougan, M., Emens, L. A., Formenti, S., Janku, F., Khleif, S. N., Kirchhoff, T., Morabito, A., Najjar, Y., Nathan, P., Odunsi, K., Patnaik, A., Paulos, C. M., Reinfeld, B. I., Skinner, H. D., Timmerman, J., & Puzanov, I. (2021). Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy). Journal of translational medicine, 19(1), Article 13. https://doi.org/10.1186/s12967-020-02627-y

Ascierto, PA, Butterfield, LH, Campbell, K, Daniele, B, Dougan, M, Emens, LA, Formenti, S, Janku, F, Khleif, SN, Kirchhoff, T, Morabito, A, Najjar, Y, Nathan, P, Odunsi, K, Patnaik, A, Paulos, CM, Reinfeld, BI, Skinner, HD, Timmerman, J & Puzanov, I 2021, 'Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)', Journal of translational medicine, vol. 19, no. 1, 13. https://doi.org/10.1186/s12967-020-02627-y

@article{2fe1e5456e0548bdb81382565b72a943,

title = "Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)",

abstract = "Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4–5 December, 2019, Naples, Italy), and are summarised in this report.",

keywords = "Biomarkers, Checkpoint inhibitors, Combination therapy, Immunotherapy, Tumor microenvironment, Vaccine",

author = "Ascierto, {Paolo A.} and Butterfield, {Lisa H.} and Katie Campbell and Bruno Daniele and Michael Dougan and Emens, {Leisha A.} and Silvia Formenti and Filip Janku and Khleif, {Samir N.} and Tomas Kirchhoff and Alessandro Morabito and Yana Najjar and Paul Nathan and Kunle Odunsi and Akash Patnaik and Paulos, {Chrystal M.} and Reinfeld, {Bradley I.} and Skinner, {Heath D.} and John Timmerman and Igor Puzanov",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12967-020-02627-y",

language = "English (US)",

volume = "19",

journal = "Journal of translational medicine",

issn = "1479-5876",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Perspectives in immunotherapy

T2 - meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)

AU - Ascierto, Paolo A.

AU - Butterfield, Lisa H.

AU - Campbell, Katie

AU - Daniele, Bruno

AU - Dougan, Michael

AU - Emens, Leisha A.

AU - Formenti, Silvia

AU - Janku, Filip

AU - Khleif, Samir N.

AU - Kirchhoff, Tomas

AU - Morabito, Alessandro

AU - Najjar, Yana

AU - Nathan, Paul

AU - Odunsi, Kunle

AU - Patnaik, Akash

AU - Paulos, Chrystal M.

AU - Reinfeld, Bradley I.

AU - Skinner, Heath D.

AU - Timmerman, John

AU - Puzanov, Igor

PY - 2021/12

Y1 - 2021/12

N2 - Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4–5 December, 2019, Naples, Italy), and are summarised in this report.

AB - Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4–5 December, 2019, Naples, Italy), and are summarised in this report.

KW - Biomarkers

KW - Checkpoint inhibitors

KW - Combination therapy

KW - Immunotherapy

KW - Tumor microenvironment

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85098760976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098760976&partnerID=8YFLogxK

U2 - 10.1186/s12967-020-02627-y

DO - 10.1186/s12967-020-02627-y

M3 - Article

C2 - 33407605

AN - SCOPUS:85098760976

SN - 1479-5876

VL - 19

JO - Journal of translational medicine

JF - Journal of translational medicine

IS - 1

M1 - 13

ER -

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this